Potency Determination for Bipathic Medicaments Using Intermediary Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliability and reproducibility in determining the potency of medicaments prepared using homeopathic techniques, particularly activated-potentiated forms, which are challenging due to their ultra-low concentrations and the inability to detect molecular forms using conventional analytical techniques.
Innovation Solution
A method involving the use of analytical techniques such as High Performance Liquid Chromatography, enzyme immune assay, and Nuclear Magnetic Resonance to measure physical, chemical, or biological parameters before and after interaction with the activated-potentiated form, expressing activity in relative units and ensuring the absence of molecular forms through dilution or molecular sieves, thereby determining the modifying potency of homeopathic medicaments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional analytical techniques are used to detect molecular forms in activated-potentiated forms, then the detection process is simple, but the reliability and reproducibility of potency determination deteriorates due to ultra-low concentrations and undetectable molecular forms
Solution Approach 1:
The patent introduces an intermediary substance (test substance) that interacts with the activated-potentiated form to produce a measurable effect. Instead of directly detecting the undetectable molecular forms, the method uses this intermediary to translate the presence and potency of the activated-potentiated form into a measurable signal, thereby resolving the detection difficulty while maintaining reliability.
Solution Approach 2:
The patent replaces conventional direct detection methods with a biological or chemical interaction system. By substituting the detection approach with an interaction-based measurement system (measuring changes in the test substance rather than directly detecting the activated-potentiated form), the method achieves reliable potency determination despite the ultra-low concentrations and undetectability of molecular forms.
2Quantity of substance
If multiple consecutive dilutions are performed to prepare activated-potentiated forms, then the concentration of molecular form decreases to ultra-low levels, but the reliability of potency determination deteriorates due to inability to detect molecular forms
Solution Approach 1:
The patent uses an intermediary test substance that can detect or interact with the activated-potentiated form even at ultra-low concentrations achieved through multiple consecutive dilutions. This intermediary allows reliable potency determination despite the extremely low quantity of molecular form present in the activated-potentiated form.
Solution Approach 2:
The patent changes the measurement parameter from direct molecular detection to measurement of interaction effects or property changes in the test substance. By measuring changes in physical, chemical, or biological parameters of the test substance rather than directly quantifying the molecular form, the method maintains reliability even when the quantity of substance is reduced to ultra-low levels.
3Quantity of substance
If homeopathic potentiation is applied to create activated-potentiated forms, then the medicament contains low or ultra-low doses of initial medicament, but the measurement precision of potency deteriorates due to concentrations below detectable limits
Solution Approach 1:
The patent introduces a test substance as an intermediary that enables precise measurement of the activated-potentiated form's potency. This intermediary allows the measurement system to detect and quantify the potency with precision even when the dose of initial medicament is reduced to low or ultra-low levels through homeopathic potentiation.
Solution Approach 2:
The patent substitutes direct concentration measurement with an interaction-based measurement system. By measuring the effect of the activated-potentiated form on the test substance (such as changes in biological activity, chemical properties, or physical parameters), the method achieves precise potency measurement despite the ultra-low concentrations that would be undetectable by conventional methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the reliability and reproducibility of assessing the potency of activated-potentiated forms by quantifying alterations in physical or biological properties, demonstrating the modifying activity associated with the carrier and confirming the authenticity of the drug product, even at concentrations below detectable limits.
Implementation Method 1
measuring at least one physical, chemical or biological parameter (A) of said molecular form of said substance using a suitable analytical method
Implementation Method 2
measuring said at least one physical, chemical or biological parameter (Am) of said treated molecular form of said substance using said analytical method
Implementation Method 3
measuring at least one physical, chemical or biological parameter (A) of said molecular form of said substance using a suitable analytical method
Implementation Method 4
multiple consecutive dilutions in a carrier (water or water-alcohol solvent)—thereby decreasing concentration
Data Source
AI summary
The invention comprises a method for determining degree of modified potency of a bipathic medicament. A bipathic medicine is a medicament comprising a therapeutic component and a homeopathic component, wherein the homeopathic component has some physical, chemical or biological affect on the therapeutic component and/or the pharmacological efficacy thereof. An analytical measurement of at least one characteristic parameter of the therapeutic form is made prior to its interaction with the activated-potentiated form. The same analytical measurement(s) are made and after interaction between the therapeutic and activated-potentiated forms. This data is used to confirm the presence of any modified potency is caused by the presence of molecular form in the activated-potentiated form. Further, the claimed analytical measurement of at least one characteristic parameter of the therapeutic form prior to its interaction with the activated-potentiated form and again after such interaction serves to quantify the degree of modifying potency associated with the activated-potentiated form in relative dimensionless activity units (release activity).